{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:18:37Z","timestamp":1788153517424,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Classic hairy cell leukemia (HCL) is a rare, indolent B-cell lymphoproliferative disorder characterized by bone marrow fibrosis causing pancytopenia, splenomegaly, and a near-universal BRAF V600E mutation. Purine nucleoside analogs (PNAs) are the standard first-line therapy but are contraindicated in patients with significantly advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD) due to renal excretion and risk of prolonged myelosuppression. Data on the use of targeted therapies, such as BRAF inhibitors, in dialysis-dependent HCL patients are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>We present a novel case of a 43-year-old man on chronic hemodialysis secondary to suspected autosomal dominant polycystic kidney disease diagnosed with classic BRAF V600E-mutated HCL, treated with low-dose vemurafenib in combination with anti-CD20 therapy. The patient achieved hematologic remission without significant renal or infectious complications. Notably, this case is further distinguished by the development of reactive macrocytic polycythemia with normal erythropoietin levels and no alternative identifiable cause, highlighting an unusual hematologic manifestation in the setting of treated HCL and end-stage renal disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This report highlights the feasibility and efficacy of BRAF-targeted therapy combined with an anti-CD20 antibody in a young dialysis-dependent HCL patient, expanding therapeutic options for this high-risk population. Further prospective studies and case series are needed to guide management in this unique clinical context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1895013","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:28:54Z","timestamp":1788150534000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision-guided therapy in dialysis-dependent classic hairy cell leukemia: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Sindhusha","family":"Veeraballi","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, University of Cincinnati Cancer Center","place":["Cincinnati, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu Bhargavi","family":"Chandra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wellstar Spalding Medical Center","place":["Griffin, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Vick","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Cincinnati Cancer Center","place":["Cincinnati, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122185","article-title":"Recommendations for the management of patients with hairy-cell leukemia and hairy-cell leukemia-like disorders: A work by French-speaking experts and French Innovative Leukemia Organization (FILO) Group","volume":"16","author":"Paillassa","year":"2024","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.078071","article-title":"Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia","volume":"98","author":"Tiacci","year":"2013","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv200","article-title":"Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up \u2020","volume":"26","author":"Robak","year":"2015","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-2-22","article-title":"Hairy cell leukemia in kidney transplantation: Lesson from a rare disorder","volume":"2","author":"Vinante","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.15761\/CCRR.1000485","article-title":"Biweekly cladribine and rituximab in a patient with hairy cell leukemia and severe renal failure","volume":"6","author":"Rankovi\u0107","year":"2020","journal-title":"Clin Case Rep Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2174\/0115748871241817230919062313","article-title":"Cladribine efficacy in a patient with hairy cell leukemia and severe renal insufficiency","volume":"18","author":"Gozzetti","year":"2023","journal-title":"Rev Recent Clin Trials"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14388","article-title":"Atypical hairy cell leukemia\u2014the current status and future directions","volume":"114","author":"Robak","year":"2025","journal-title":"Eur J Haematol"},{"key":"B10","unstructured":"Hairy cell leukemia: A clinical review based on 725 cases of the Italian cooperative group (ICGHCL)\n          \n          10.3109\/10428199409056295"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2140-y","article-title":"Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia","volume":"93","author":"Cornet","year":"2014","journal-title":"Ann Hematol"},{"key":"B12","unstructured":"How I treat refractory\/relapsed hairy cell leukemia with BRAF inhibitors\n          \n          10.1182\/blood.2021013502\n          American Society of Hematology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk030","article-title":"Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: A population-based study","volume":"99","author":"Hisada","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002160","article-title":"Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: A SAKK trial","volume":"4","author":"Benz","year":"2020","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157780","article-title":"The biology of classic hairy cell leukemia","volume":"22","author":"Bohn","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27240","article-title":"Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-annual updates in hematological Malignancies","volume":"99","author":"Troussard","year":"2024","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"127","author":"Dietrich","year":"2016","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01210-8","article-title":"Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: A pilot phase-2 clinical trial","volume":"35","author":"Tiacci","year":"2021","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1182\/blood.2021013658","article-title":"Dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600E mutation-positive hairy cell leukemia","volume":"141","author":"Kreitman","year":"2023","journal-title":"Blood"},{"key":"B20","unstructured":"Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia\n          \n          10.1056\/NEJMoa2031298"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300074","article-title":"Vemurafenib and Obinutuzumab as frontline therapy for hairy cell leukemia","volume":"2","author":"Park","year":"2023","journal-title":"NEJM Evid"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009688","article-title":"Phase 2 study of ibrutinib in classic and variant hairy cell leukemia","volume":"137","author":"Rogers","year":"2021","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008990","article-title":"Zanubrutinib for the treatment of relapsed\/refractory hairy cell leukemia","volume":"7","author":"Tam","year":"2023","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2216135","article-title":"Venetoclax in relapsed or refractory hairy-cell leukemia","volume":"388","author":"Tiacci","year":"2023","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1728452","article-title":"Immune activation and microenvironmental crosstalk in hairy cell leukemia","volume":"16","author":"Tanzeem","year":"2026","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0523-7","article-title":"Clinical pharmacokinetics of vemurafenib","volume":"56","author":"Zhang","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-581","article-title":"Safety and efficacy of vemurafenib in end stage renal failure","volume":"13","author":"Iddawela","year":"2013","journal-title":"BMC Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15514","article-title":"Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant","volume":"19","author":"Redfield","year":"2019","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"B30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/omcr\/omw005","article-title":"Hairy cell leukemia followed by polycythemia vera: Report of the first case","volume":"2016","author":"Ipek","year":"2016","journal-title":"Oxf Med Case Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13256-018-1663-6","article-title":"Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: A case report","volume":"12","author":"Habberstad","year":"2018","journal-title":"J Med Case Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41392-024-02033-6","article-title":"BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling","volume":"9","author":"Wu","year":"2024","journal-title":"Sig Transduct Target Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895013\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:28:55Z","timestamp":1788150535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895013\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1895013"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1895013","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1895013"}}